Immunotherapy change overcomes acquired resistance after chemo-immunotherapy in unresectable biliary tract cancer.

ABSTRACT:

Purpose

To assess the incidence, clinical characteristics, and post-progression management strategy of resistance to immunotherapy-chemotherapy combination in unresectable biliary tract carcinoma (uBTC).

Experimental

DESIGN: Patients with uBTC from multiple centers who received immunotherapy-chemotherapy combination were retrospectively included. Baseline characteristics, treatments, pattern of progression, and posttreatment managements were recorded. The primary endpoint was post-progression survival (PPS).

Results

Out of 194 patients, 130 (67.0%) developed resistance, including 78 (40.2%) with acquired resistance (AR) and 52 (26.8%) with primary resistance (PR). Normal CA19-9 level and combining target therapy were more common in patients with AR. Patients with both

SUBMITTER: Chen X 

PROVIDER: S-EPMC12480270 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature